Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The term **"Vitamin C pathway"** does not refer to a single molecular target such as a receptor, enzyme, transporter, or gene product. Instead, it encompasses all biochemical processes involved in the absorption, transport, cellular uptake, utilization (as an antioxidant and enzymatic cofactor), recycling/regeneration of reduced ascorbate from oxidized forms (dehydroascorbate), and eventual degradation/excretion of vitamin C. In humans and other primates who cannot synthesize vitamin C endogenously due to loss of L-gulonolactone oxidase activity[2], this network includes: • **Transporters:** Sodium-dependent vitamin C transporters SVCT1/SLC23A1 (intestinal/renal) and SVCT2/SLC23A2 (tissue uptake); glucose transporters GLUT1/GLUT3/GLUT4 mediate dehydroascorbate uptake via facilitated diffusion[1][3]. • **Enzymes:** Multiple monooxygenases/dioxygenases requiring ascorbate as a reducing agent/cofactor—key examples include prolyl hydroxylase for collagen synthesis; dopamine β-monooxygenase for norepinephrine production; enzymes involved in carnitine biosynthesis; peptidylglycine α-amidating monooxygenase for peptide hormone maturation; tyrosine metabolism enzymes[7]. • **Antioxidant function:** Ascorbate donates electrons directly to neutralize reactive oxygen species/free radicals generated during normal metabolism or under stress conditions. It also regenerates other antioxidants such as vitamin E from their oxidized forms.[5] Because “Vitamin C pathway” refers collectively to these interconnected processes rather than any one discrete molecular entity that could be considered a drug target per se—and because it lacks specificity regarding which component(s) are meant—it should be flagged as incorrect when compiling structured data on therapeutic targets. In summary: The “Vitamin C pathway” describes an essential metabolic network rather than an individual therapeutic target. For structured information about druggable targets within this system—such as sodium-dependent vitamin C transporter 1 (SVCT1), sodium-dependent vitamin C transporter 2 (SVCT2), or specific dioxygenases—a more precise name should be used.[1][3][9]
Not applicable for the pathway as a whole; vitamin C acts as an antioxidant and enzyme cofactor within this network[3][5]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Vitamin C pathway.